Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Tumors × Infusions, Intravenous × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2 Solid Tumors 1 Recurrence 1 Myelodysplastic Syndromes 1 Metastatic Solid Tumors 1 Leukemia, Myelomonocytic, Chronic 1 Advanced Malignant Neoplasm 1

Interventions

pembrolizumab 4 Nivolumab 2 Injections 2 Docetaxel 2 taxane 1 pazopanib 1 palbociclib 1 lenvatinib 1 demplatin pegraglumer 1 cobimetinib 1 birinapant 1 Topotecan 1 Tablets 1 ODM-207 1 Infusions, Intravenous 1 HLA-A*24:02 antigen 1 Gemcitabine 1 E-3810 1 CB-839 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05524194 2022-09-01

6MW3511 in Patients With Advanced Solid Tumor

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡